Keller Rohrback L.L.P. Announces Investigation of Lung and Liver Problems Potentially Associated with Recalled Children’s

SEATTLE--(BUSINESS WIRE)-- Attorney Advertising. Keller Rohrback L.L.P. (www.krclassaction.com) announces that it is investigating possible claims against Johnson & Johnson (NYSE: JNJ), and its McNeil-PCC, Inc. Division (the “Company”), related to the Company’s recalls of children’s and infants’ liquid medications due to the possibility that these medications cause lung and liver problems.

The Company most recently recalled the medications following an April 2010 inspection by the Food and Drug Administration (“FDA”). In the inspection report, the FDA observed the presence of Burkholderia cepacia bacteria. The FDA further observed super potent batches that contained more of the active ingredient (acetaminophen) than represented, because there was no product mixing procedure to assure uniformity and homogeneity in these medications. The Company also recalled children’s and infants’ liquid medications in September 2009, again based upon the presence of Burkholderia cepacia bacteria.

Burkholderia cepacia bacteria can cause pneumonia in immunocompromised individuals with an underlying lung condition. Infants and children with underlying lung conditions such as cystic fibrosis, obstructive lung disease, or chronic granulomatous disease may be particularly susceptible to pneumonia caused by these bacteria. Burkholderia cepacia bacteria are unfortunately resistant to some widely used antibiotics and can also survive topical antiseptics. In the worst case scenario, Burkholderia cepacia bacteria can cause lung function to become severely compromised, leading to the patient’s death.

Sustained use of super potent doses of acetaminophen is also a concern as taking more than the recommended dose of acetaminophen may cause liver damage.

Keller Rohrback is currently investigating possible claims against the Company pertaining to its recall of the following liquid medications:

  • Tylenol® brand Infants’ Drops, Children’s Suspensions, and Children’s Plus Suspensions;
  • Motrin® brand Infants’ Drops, Children’s Suspensions, and Children’s Cold Suspensions;
  • Children’s Zyrtec®; and
  • Children’s Benadryl®.

If you purchased any of these products and have concerns about lung or liver problems, please contact paralegal Katie Grant or attorneys Amy N.L. Hanson or Lynn Sarko at 800-776-6044 or 206-442-1556 or via email at [email protected].

Keller Rohrback, with offices in Seattle, Phoenix, and New York, has successfully pursued claims against product manufacturers and pharmaceutical companies on behalf of our injured clients, as well as achieved multi-million dollar results.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.



CONTACT:

Keller Rohrback L.L.P.
Katie Grant, Paralegal, 800-776-6044
[email protected]
http://www.krclassaction.com

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Baby/Maternity  Children  Legal  FDA  Consumer

MEDIA:

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.